Aclaris Therapeutics (ACRS – Research Report) received a Hold rating and price target from BTIG analyst Julian Harrison yesterday. The company’s shares closed last Friday at $0.92.
According to TipRanks, Harrison is a 5-star analyst with an average return of 18.5% and a 57.14% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, CymaBay Therapeutics, and Aclaris Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Aclaris Therapeutics with a $3.25 average price target, representing a 251.73% upside. In a report released on January 10, Jefferies also downgraded the stock to a Hold with a $1.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Aclaris Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $9.28 million and a GAAP net loss of $29.26 million. In comparison, last year the company earned a revenue of $19.02 million and had a GAAP net loss of $19.95 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aclaris Therapeutics (ACRS) Company Description:
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
Read More on ACRS:
- Aclaris Therapeutics downgraded to Neutral from Buy at BTIG
- Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
- Aclaris Therapeutics downgraded to Hold from Buy at Jefferies
- Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
- Aclaris announces Phase 2b study of ATI-1777 met primary efficacy endpoint
